Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening
- 31 August 2004
- Vol. 64 (2) , 317-322
- https://doi.org/10.1016/j.urology.2004.03.018
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control studyInternational Journal of Cancer, 2004
- Prostate Testing for Cancer and Treatment (ProtecT) feasibility studyHealth Technology Assessment, 2003
- Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate BiopsyJournal of Urology, 2002
- Insulin‐like growth factors and risk of benign prostatic hyperplasia†The Prostate, 2002
- Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective StudyJNCI Journal of the National Cancer Institute, 2000
- Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?The Lancet, 2000
- Serum insulin‐like growth factor‐1 is not a useful marker of prostate cancerBJU International, 1999
- Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic DiseaseJAMA, 1998
- Maximum-likelihood estimation of parameters of signal-detection theory and determination of confidence intervals—Rating-method dataJournal of Mathematical Psychology, 1969